Protocol AI447029: A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa- 2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are /Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin with Chro